: iStockAnalyst.com Symbols Feed

15 Breakout Stocks On Huge Volume

Thu, 08 Oct 2009 13:46:16 GMT

Here is a list of 15 stocks which traded higher Wednesday on unusually higher volume. I have added all 15 of these stocks to my watch list (and invite you to as well), but chose only a couple to write about in detail in this post. This post requires the knowledge of stock options.[More...]

Enzon Faces Shareholder Pressure

Tue, 10 Feb 2009 14:31:00 GMT

Enzon Pharmaceuticals (NDAQ: ENZN) may face another board shake-up after an activist investor requested that its nominees be added to the board of directors. DellaCamera Capital, which owns a 7.6% stake in the firm, and suggested that its nominees would “breathe new life into a board that has been unable to reverse the decline in shareholder value” in a Schedule 13D/A filing with the SEC. Here’s a copy of the letter to the board: Your failure to date to contact the two board candidates that we have nominated is another missed opportunity to avail yourself of[More...]

Enzon Pharma Shares Rise on Prospects

Fri, 21 Nov 2008 20:33:00 GMT

Enzon Pharmaceuticals, Inc. (NDAQ: ENZN) shares moved higher after a large investor disclosed that they hired an advisor to explore strategic alternatives for the company in a Schedule 13D filing with the SEC. DellaCamerca Capital Master Fund engaged the investment banking firm Moelis & Company LLC to explore strategic alternatives with respect to the investment in the company. The 7.8% shareholder is likely attempting to find a buyer to boost the share price. Last quarter, Enzon reported strong results and a net loss of just $2 million or $0.05 per share. The third quarter results were impacted by the $88.7 million net gain from the sale of a portion of their PEG-INTRON royalty asset. All in all, the company remains strong and continues to see growth and stability in their marketed products. Unfortunately, the volatile external[More...]

Analyst Comments: Enzon Pharma, BHP Billiton, Lincoln Electric, Hologic, Ardea Biosciences, Gafisa, Buckeye Partners, Take-Two

Mon, 18 Aug 2008 18:50:00 GMT

Enzon Pharmaceuticals? (ENZN) key product Abelcet, a treatment for fungal infections, sales continued to deteriorate in 2008. Further, another major source of revenue, Royalty, is also under pressure from competition. However, sales in two other products, Oncaspar (for acute lymphoblastic leukemia) and Adagen (for severe combined immunodeficiency disease) are picking up momentum and offsetting the sales decline from Abelcet and Royalty. We are impressed with strong sales growth of Oncaspar. We expect total revenue to remain stable or experience modest growth in the coming years while the company is progressing well with its clinical developments. Enzon is also advancing its pipeline to drive long-term growth. We maintain our Hold rating on the shares. We see a balanced risk/reward profile for Enzon. In our view, there are limited near-term catalysts to[More...]

Periodicals Wrap-Up for Monday, August 11th

Mon, 11 Aug 2008 14:23:00 GMT

Posted By Optiondragon for Myhappytrading.com- The best social network for traders on the internet! Made BY Awesome Traders for Awesome Traders.[More...]

Baxter CEO Parkinson Suggests Criminal Intent with regard to Heparin Contamination

Tue, 29 Apr 2008 22:49:43 GMT

(NewsVisual, powered by IntellectSpace) -- In what sounds like grounds for a criminal investigation, the head of Baxter International Inc (NYSE: BAX) said in public for the first time that the tainting of the company’s heparin drug was probably deliberate[More...]

Icahn Files 13D on Enzon Pharma

Fri, 14 Mar 2008 17:22:20 GMT

Carl Icahn filed a 13D regarding his stake in Enzon Pharmaceuticals (ENZN) today. Icahn now may be deemed to beneficially own, in the aggregate, 3,072,103 Shares, representing approximately 6.93% of Enzon's outstanding Shares (based upon the 44,322,923 SharesAlso,"The Reporting Persons have entered into a number of derivative agreements, commonly known as Total Return Swaps, with counterparties, which agreements provide that the profit to the Reporting Persons shall be based upon the increase in value of the Shares and the loss to the Reporting Persons shall be based upon the decrease in the value of the Shares, during the period from inception of the applicable agreement to its termination. The agreements provide that they settle in cash. In addition to the Shares which they beneficially own as shown in Item 5 above, the Reporting Persons currently have long economic exposure to an agg[More...]

Baxter CEO Faces Crucial Challenge Posed by Drug Contamination

Wed, 05 Mar 2008 19:49:52 GMT

(NewsVisual, powered by IntellectSpace) -- When one considers what’s the worst bad thing that could happen to a drug company, it would have to be something along the lines of the news that Baxter International Inc (NYSE: BAX) received from the Food and Dr[More...]

Analyst Comments: Kansas City Southern, Sara Lee, Magna International, eBay, Intuitive Surgical, Enzon, AvalonBay, Daimler AG

Fri, 04 Jan 2008 16:34:34 GMT

An update has just come out on Kansas City Southern (KSU), in which senior transportation sector analyst Ann H. Heffron, CFA is restating her Hold rating on the company. We excerpted the following details:'KSU is expected to post fourth quarter results on February 5. We are continuing our diluted EPS estimates at $1.50 for 2007and $1.80 for 2008. Results should...[More...]

Enzon Pharmaceuticals Q2 Net Loss Widens

Thu, 06 Aug 2009 15:53:00 GMT

Enzon Pharmaceuticals has reported a net loss of $5.1 million, or $0.11 per diluted share, for the second quarter ended June 30, 2009, compared to a net loss of $1.74 million, or $0.04 per diluted share, for the second quarter of 2008.
Operating loss was $3.45 million, compared to an operating income of $377,000 in the second quarter of 2008.
Jeffrey Buchalter, president and CEO of Enzon Pharmaceuticals, said: "We are pleased with the advancement of our innovative pipeline, particularly our novel PEG-SN38 compound, which is now enrolling patients in phase II.

[More...]

Enzon Reports 2nd Quarter 2009 Results

Tue, 04 Aug 2009 12:20:00 GMT

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the second quarter of 2009. For the three months ended June 30, 2009, Enzon reported a net loss of $5.1 million or $0.11 per diluted share, as compared to a net loss of $1.7 million or $0.04 per diluted share for the second quarter of 2008. The 2009 financial results were impacted by the anticipated investment in R&D including PEG-SN38 and the next-generation Oncaspar program, as well as lower royalty and contract manufacturing revenues.[More...]

CORRECTING and REPLACING Enzon to Present at BMO Focus on Healthcare Conference

Tue, 28 Jul 2009 13:29:00 GMT

In first graph of release dated July 27, 2009, date should be Wednesday, August 5 (sted Tuesday, August 4).[More...]

Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow

Mon, 27 Jul 2009 16:56:00 GMT

Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended June 30, 2009, on Tuesday, August 4, 2009 at approximately 8:00 am Eastern Time (ET). The release will be followed by a live conference call, which will begin at approximately 9:00 am Eastern Time (ET) on Tuesday, August 4, 2009.[More...]

Enzon to Present at BMO Focus on Healthcare Conference

Mon, 27 Jul 2009 14:21:00 GMT

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Jeffrey H. Buchalter, Enzon’s president and chief executive officer, will present at the 2009 BMO Capital Markets 9th Annual Focus on Healthcare Conference, which is being held August 4th in New York City. Enzon’s presentation will take place at 9:30 a.m. EST on Tuesday, August 4, 2009. The presentation will be webcast. Interested parties can access the webcast information by going to the events page that is under shareholder information on Enzon’s website at www.enzon.com.[More...]

DellaCamera Comments on Recent Replacement of Jeffrey H. Buchalter as Chairman of Enzon and Addition of New Independent Director to Enzon’s Board

Thu, 23 Jul 2009 20:41:00 GMT

DellaCamera Capital Management, LLC (“DellaCamera”) and related entities, which beneficially hold approximately 8.3% of the shares of Enzon Pharmaceuticals, Inc. (“Enzon” or the “Company”) (NASDAQ: ENZN), today announced that it is encouraged by the recent actions taken by the Enzon Board of Directors (the “Board”) and the Company’s announcement that it has formally separated the roles of Chairman and CEO and named Dr. Alexander J. Denner, a representative of affiliated entities of Carl Icahn and previous Chairman of the Executive Committee of ImClone Systems Incorporated, to replace Jeffrey H. Buchalter as Chairman of the Board. DellaCamera is also encouraged by the fact that its efforts have led to the addition of Harold J. Levy, co-CEO of Iridian Asset Management LLC, the Company’s largest shareholder, as a new, independent member to the Board.[More...]

Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director

Thu, 23 Jul 2009 20:29:00 GMT

Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN) announced that in an effort to enhance corporate governance, it has added a new position of non-executive Chairman of the Board. The Company has also expanded the board with one new independent Director.[More...]

DellaCamera Advised That Enzon Has Set July 24, 2009 as Record Date for Consent Solicitation

Tue, 21 Jul 2009 20:04:00 GMT

DellaCamera Capital Management, LLC (“DellaCamera”) and related entities, which beneficially hold approximately 8.3% of the shares of Enzon Pharmaceuticals, Inc. (“Enzon” or the “Company”) (NASDAQ: ENZN), announced today that DellaCamera has been advised by counsel to Enzon that the Board of Directors has set July 24, 2009 as the record date in order to determine which Enzon stockholders are entitled to act by written consent in regards to DellaCamera’s consent solicitation to amend Enzon’s By-laws and to remove Enzon CEO and President Jeffrey H. Buchalter.[More...]

DellaCamera Makes Formal Request for Enzon to Set Record Date for Consent Solicitation

Tue, 07 Jul 2009 16:02:00 GMT

Enzon Commences Phase II Trial of PEG-SN38

Mon, 22 Jun 2009 19:56:00 GMT

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has opened its first Phase II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients diagnosed with metastatic colon cancer.[More...]

DellaCamera Reports on Town Hall Meeting for Enzon Shareholders and Provides Update on Consent Solicitation Process

Wed, 17 Jun 2009 14:00:00 GMT

DellaCamera Capital Management, LLC (“DellaCamera”) and related entities, which beneficially hold approximately 8.3% of the shares of Enzon Pharmaceuticals, Inc. (“Enzon” or the “Company”) (NASDAQ: ENZN), today reported on its recent Town Hall Meeting and provided an update to all Enzon shareholders on the consent solicitation process to remove Enzon CEO and President Jeffrey H. Buchalter.[More...]